Ambisome® Preemptive Treatment of Multiple Candida Colonization in Sepsis Patients
Status:
Unknown status
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
To assess the safety of Ambisome 10 mg/kg/week in patients as a preemptive treatment in
intensive care patients with a sepsis and rising candida colonisation.
Preemptive treatment (i.e., prophylactic treatment with two high doses of Ambisome®
administered with an interval of one week, in patiens with a high risk of developing a fungal
infection) should decrease the incidence of actual systemic infections.
The incidence of such actual fungal infections will be assessed directly and its impact on
patients' survival and intensive care resourches assessed